

O I P E

OCT 12 2001

<110> Schenk, Dave B.
NeuroLab, Inc.
NeuroLab, Inc.

SEQUENCE LISTING

RECEIVED

NOV 08 2001

TECH CENTER 1600/2900

<120> Prevention and Treatment of Amyloidogenic Disease

<130> 15270J-004740US

<140> 09/322,289

<141> 1999-05-28

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<223> human Abeta42 beta-amyloid peptide

<400> 1

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala
35 40

<210> 2

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Abetal-12
peptide with carboxyl terminal Cys residue
inserted

<400> 2

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
1 5 10

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Abetal-5
peptide with carboxyl terminal Cys residue
inserted

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

<400> 3
Asp Ala Glu Phe Arg Cys
1 5

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Abeta33-42
peptide with carboxyl terminal Cys residue
inserted

<220>
<221> MOD_RES
<222> (2)
<223> Xaa = amino heptanoic acid

<400> 4
Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
1 5 10

<210> 5
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Abeta13-28
peptide with carboxyl terminal Cys residue
inserted and two added Gly residues

<220>
<221> MOD_RES
<222> (1)
<223> Xaa = acetyl histidine

<400> 5
Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
1 5 10 15

Gly Gly Cys